
News|Articles|March 1, 2008
FDA pipeline preview, March 2008
FDA-related information through March 2008 on C1 inhibitor, ferric carboxymaltose injection, lovastatin, carbidopa/levodopa extended release, vigabatrin, bortezomib, peginterferon alfa-2b, elesclomol, triphendiol, VQD-002
Advertisement
Complete response letter
Recommended for approval
Nonapprovable designations
Fast-track designations
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Stanford scientists find link between Epstein-Barr virus and lupus
2
Biosimilar denosumab could save $0.59 per member per month
3
Transparency paves the way for lower costs and equitable access
4
Racial differences in treatment priorities highlight opportunity to strengthen shared decision-making in lung cancer care
5






















































